Natera

We’re pleased to share that new results from RenaCARE, the largest prospective study to date assessing the clinical utility of genetic testing for chronic kidney disease (CKD), have been published in the Journal of the American Society of Nephrology (JASN). The study demonstrates how nephrologists used Renasight™ – a comprehensive genetic test that helps identify the underlying genetic cause of CKD by analyzing hundreds of kidney-related genes – to guide diagnosis, prognosis and family risk assessment for adults with CKD. One year after genetic testing with Renasight, nephrologists reported that results were helpful for clinical management and/or led to a change in care in 86% of patients with a positive test finding, and 42% of patients with a negative test finding. This publication builds on the one-month post-test findings published in JASN in 2023 and demonstrates that Renasight testing can provide nephrologists with a better understanding of disease risk and insight into management strategies across a spectrum of CKD-related conditions. Congratulations to the clinicians, investigators and Naterans who made this milestone possible. Read the publication: https://ow.ly/mEHB50XFRH7 Learn more about Renasight: https://ow.ly/cjSe50XFUsK #KidneyDisease #Nephrology #Natera #Renasight American Society of Nephrology

Natera and Foresight Diagnostics joined together as one team for the first time at The American Society of Hematology (ASH) Annual Meeting, marking a memorable debut with 15 scientific posters, including seven oral presentations. Of note, two oral presentations reinforced how the ultrasensitive detection of disease at the molecular level can support more personalized treatment and surveillance strategies for patients with lymphoma. First, a real-world analysis of personalized circulating tumor DNA (ctDNA) detection in lymphoma evaluated 144 patients across 14 lymphoma subtypes, including aggressive and indolent lymphomas and patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy. Signatera™ was used clinically to assess baseline ctDNA detection, track molecular clearance during first-line therapy, and evaluate end-of-treatment ctDNA status and post-CAR-T response. Additionally, the HOVON-902 study was conducted by Foresight in collaboration with Amsterdam University Medical Centers, the Hemato-Oncology Foundation for Adults in the Netherlands (HOVON) and the Netherlands Comprehensive Cancer Organization (IKNL). The study evaluated longitudinal molecular residual disease (MRD) surveillance in 166 patients with diffuse large B-cell lymphoma. The study provided one of the most detailed evaluations to date of ctDNA-MRD dynamics over a two-year surveillance period using Foresight's PhasED-Seq™ ctDNA Technology. Read more about these results: https://ow.ly/ncM350XHcvk #ASH25

Carrier screening is no longer just about reproductive risk. New research shows some carriers during pregnancy may face their own health impacts. As testing expands, clearer guidance, counseling, and support are needed. Learn more from Lauren Tuttle, MS, LCGC https://lnkd.in/gyNi7Y6B #Sponsored #GeneChat

Today, Natera announced the acquisition of Foresight Diagnostics, a leader in ultrasensitive MRD detection. This combination brings together Foresight’s phased variant technology with Natera’s Signatera™ platform to further strengthen performance across both solid tumors and hematologic cancers. Founded in 2020 by physicians and scientists from Stanford University, Foresight has developed MRD assays using an innovative and patented technology, which delivers advanced sensitivity by tracking phased variants. With this approach, Foresight has detected ctDNA at ultrasensitive levels. The integration of phased variants into Signatera is now available for research use and is expected to launch clinically in 2026. The acquisition also expands our leadership in lymphoma, where Foresight has built a strong scientific foundation, including data that helped drive the inclusion of ctDNA MRD into NCCN® guidelines for diffuse large B-cell lymphoma. At this year’s ASH annual meeting, starting tomorrow, our combined teams will present 15 abstracts, underscoring the momentum behind our approach to personalized MRD testing. We’re excited for the impact this will have on accelerating innovation and improving care for patients worldwide. We’re also thrilled to welcome Foresight and the company’s incredibly talented team to Natera! https://ow.ly/Wqr450XCIgr

We're excited to announce an incredibly impactful list of studies highlighting Signatera™ that will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) next week. The presentations encompass aggregated data from >50K patients in real-world evidence and prospective clinical studies, demonstrating the prognostic and predictive power of Signatera across diverse breast cancer subtypes and settings. These include real-world studies of Signatera adoption and clinical impact at Yale, Houston Methodist and other leading institutions. Learn more: https://ow.ly/YsP450XASC9 #SABCS25 #Natera San Antonio Breast Cancer Symposium

Kyle’s experience with stage IV colon cancer underscores the role of early detection and personalized care. With the help of Signatera™ MRD testing, Kyle’s care team identified recurrence before imaging could and took swift action. See his full story: https://ow.ly/wpbl50XAbOX #MRDtesting #Natera

A heartfelt thank you to our amazing Natera employees who gave back during Volunteer Month! 💙 Together, we contributed 1,500+ volunteer hours across the U.S., supporting various organizations including food banks, cancer advocacy groups and animal shelters. Since 2021, Naterans have volunteered 28,500+ hours, an incredible commitment to important causes close to our hearts. We are so grateful for the generosity of our teams and their work to change the world!

“Signatera empowers me to be my own best advocate with my oncologists - it’s given me peace of mind.” — JoAnn, lung cancer survivor. Signatera™ helps lung cancer survivors like JoAnn stay ahead of recurrence and track treatment response with confidence. Hear JoAnn’s story: https://ow.ly/xNAm50Xl270 #LungCancerAwarenessMonth #LungCancerSurvivor #Signatera #MRDtesting #ctDNA #Natera #PatientStories #PrecisionMedicine

Exciting news: Natera has been ranked #1 on The Healthcare Technology Report's list of the Top 50 Healthcare Technology Companies of 2025! This recognition is a testament to our incredible teams whose innovation, collaboration and commitment to patients continue to raise the bar in precision medicine. From oncology to women’s health to organ health, your work is transforming care for people around the world. Congratulations to every Nateran who helped make this possible! https://ow.ly/8ZpS50Xu4rX

Join our upcoming webinar, From detection to direction: Signatera™ MRD testing and its impact in CRC. Experts will unpack how Signatera is shaping treatment escalation, post-adjuvant surveillance strategies and metastasis-directed therapy using personalized tumor-informed MRD testing. Featured speakers: Robert Lentz, Medical Oncologist GI Medical Director, Natera Mark Lewis, MD, Medical Oncologist Director of Gastrointestinal Oncology, Intermountain Healthcare Associate Professor at the University of Utah https://ow.ly/2h9L50XtEgc #Natera #Signatera #Oncology